Lv52
840 积分 2021-12-16 加入
感谢科研通大公无私。
Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer
7小时前
待确认
Low-Dose CT Screening in East Asian Women Who Have Never Smoked: Association between Family History of Lung Cancer and Ground-Glass Nodule Prevalence and Growth
14天前
已完结
Growth and Clinical Impact of 6-mm or Larger Subsolid Nodules after 5 Years of Stability at Chest CT
14天前
已完结
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials
16天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
17天前
已完结
Recurrence and Emergence of New Primary Tumors in Patients with Resected Pathological Stage 1A Non-Small Cell Lung Cancer
27天前
已完结
Recurrence and Emergence of New Primary Tumors in Patients with Resected Pathological Stage 1A Non-Small Cell Lung Cancer
27天前
已关闭
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer
28天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已关闭
皖公网安备34019202002308
